Abstract Number: 1268 • ACR Convergence 2025
Development of the LupusCoach Chatbot: Results of a Focus Group
Background/Purpose: Self-management education and coaching are successful interventions for managing chronic health conditions. However, accessibility of in-person coaching is limited; digital coaching is available and…Abstract Number: 1070 • ACR Convergence 2025
Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center
Background/Purpose: Women with SLE are at an increased risk of developing cervical cancer, primarily by human papillomavirus (HPV) and immunosuppression. This elevated risk has been…Abstract Number: 0945 • ACR Convergence 2025
Nerve Injury-Induced Protein-1 (Ninj1) Deficiency Aggravates Murine Lupus Through Modulation of Macrophage Polarization
Background/Purpose: Nerve injury-induced protein-1 (Ninj1) is an adhesion molecule that plays various roles in immune and stromal cells, including the modulation of inflammation and a…Abstract Number: 0905 • ACR Convergence 2025
Development and Characterization of IAR130, a 2+1 Format, CD19 and BCMA Dual Targeting T Cell Engager for Autoimmune Diseases
Background/Purpose: Immune reset, achieved through profound and sustained depletion of B cells and/or plasma cells, has demonstrated significant clinical efficacy in patients with severe and…Abstract Number: 0649 • ACR Convergence 2025
Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
Background/Purpose: Belimumab, a B-cell modulator monoclonal antibody that selectively inhibits BLyS and reduces autoreactive B-cells that drive lupus disease activity, has consistently demonstrated improved efficacy…Abstract Number: 0629 • ACR Convergence 2025
Characterizing Arthritis Subtypes in SLE: Prevalence, Clinical Features, and the Role of Type I Interferon Signatures
Background/Purpose: We aimed to study the prevalence of subtypes of lupus arthritis and determine their association with clinical features, serology, and type I interferon signature.Methods:…Abstract Number: 0612 • ACR Convergence 2025
Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Background/Purpose: Antimalarials, particularly hydroxychloroquine, are a cornerstone of systemic lupus erythematosus (SLE) management, with well-established benefits including reduced disease activity, prevention of flares, and mitigation…Abstract Number: 0596 • ACR Convergence 2025
Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort
Background/Purpose: Previous studies have shown that male gender is an independent predictor of organ damage in patients with systemic lupus erythematosus (SLE), particularly in the…Abstract Number: 0802 • ACR Convergence 2025
Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
Background/Purpose: Cutaneous manifestations of lupus are highly prevalent and have a significant impact on patients’ physical and mental health and wellbeing; however, no targeted therapy…Abstract Number: 0218 • ACR Convergence 2025
Creating an EHR Lupus Outreach Workbench to Address Care Gaps
Background/Purpose: Lupus affects up to 1.5 million people in the US with significant health disparities in care and outcomes that call for care delivery innovation.…Abstract Number: 0023 • ACR Convergence 2025
Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
Background/Purpose: Hydroxychloroquine (HCQ) is routinely prescribed for treatment of systemic lupus erythematosus (SLE) due to its efficacy at decreasing disease activity/SLE flares and strong benefit:risk…Abstract Number: 2695 • ACR Convergence 2025
B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents
Background/Purpose: Advanced protein-based therapies targeting B-cells, including glycoengineered CD20 monoclonal antibody obinutuzumab (OBI) and the CD19/CD3 T-cell engager blinatumumab (BLI), show promise for managing severe…Abstract Number: 2629 • ACR Convergence 2025
Predictors of 30-day Readmissions in Pregnant Patients with Systemic Lupus Erythematosus: The Impact of Social Determinants of Health.
Background/Purpose: Social Determinants of Health (SDOH) are increasingly recognized as significant contributors to adverse outcomes in pregnant patients with SLE. This study aims to evaluate…Abstract Number: 2469 • ACR Convergence 2025
Development of Consensus Statements on Glucocorticoid Use in Systemic Lupus Erythematosus
Background/Purpose: Systemic glucocorticoid (GC) therapy is indispensable for treating active systemic lupus erythematosus (SLE) and lupus nephritis (LN), while contributing significantly to comorbidities and irreversible…Abstract Number: 2451 • ACR Convergence 2025
Tofacitinib Lowers Markers of Photosensitivity in Patients with Cutaneous Lupus Erythematosus
Background/Purpose: Photosensitivity lowers quality of life in patients with cutaneous lupus erythematosus (CLE) and puts patients with systemic lupus erythematosus (SLE) at risk of systemic…
ACR Meeting Abstracts